Outset Medical Inc. reported its first quarter 2025 financial results, highlighting a revenue increase to $29.8 million, a 6% rise from $28.2 million in the same quarter of 2024. Product revenue reached $21.3 million, showing a 4% growth from $20.4 million in the prior year. The company emphasized the strong progress in its commercial transformation and operational execution. Additionally, Outset reiterated its 2025 revenue guidance, projecting between $115 million and $125 million, with a non-GAAP gross margin expected in the high-30% range. The company also anticipates using less than $50 million in cash for 2025, a reduction from the $103 million used in 2024. CEO Leslie Trigg noted the growth in console placements and utilization-driven recurring revenue, along with the expansion of their installed base in both acute and home hemodialysis settings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.